Cellectis To Present Preliminary Results Of NATHALI_01 And Updated Results Of The BALLI_01 Phases I Trials At The American Society Of Hematology 65th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Cellectis (CLLS) announced preliminary results of the Phase I NATHALI-01 and updated results of the Phase I BALLI-01 clinical trials. The trials evaluate UCART20x22 and UCART22 respectively, in patients with relapsed or refractory non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The data will be presented at the American Society of Hematology 65th Annual Meeting. The initial data supports the continued clinical trial evaluating UCART20x22. UCART22 Process 2, manufactured in-house by Cellectis, showed a higher preliminary response rate compared to UCART22 Process 1, manufactured by an external CDMO.
November 02, 2023 | 9:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis announced positive preliminary and updated results from their Phase I clinical trials. The data supports the continued evaluation of UCART20x22 and UCART22 Process 2, which could potentially lead to future revenue streams if the trials are successful.
The announcement of positive preliminary and updated results from the Phase I clinical trials is a positive development for Cellectis. The data supports the continued evaluation of UCART20x22 and UCART22 Process 2, which could potentially lead to future revenue streams if the trials are successful. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100